Matt Galsky, MD, delved into the recent approval of a perioperative durvalumab regimen in muscle-invasive bladder cancer.

Uday R. Popat, MD, discusses promising findings from a phase 2 trial evaluating the JAK inhibitor itacitinib combined with ...

The FDA has approved an investigational device exemption (IDE) application for the start of a pilot study evaluating the ...

Meredith McKean, MD, MPH, discusses the background and goals from the recent long-term follow-up of a phase 1 study evaluating the combination of fianlimab and cemiplimab in advanced melanoma.

During a live event, Payal D. Shah, MD, discusses the case of a woman with metastatic breast cancer and the data for ...

Following a successful Type B end-of-phase 2 meeting, the FDA has approved the start of a phase 3 trial of linperlisib in peripheral T-cell lymphoma.

Julie Gralow, MD, FACP, FASCO, explains that a combination of the growing US population and the increasing rate of clinicians reporting burnout and retiring early are major factors contributing to the ...

Panelists discuss how, when a patient progresses to second-line therapy, key considerations include prior treatment response, toxicity, patient comorbidities, and therapeutic goals. Lenvatinib shows ...

Amit Gupta, MD, discussed a new collaboration between University Hospitals Cleveland Medical Center and Qure.ai that aims to ...

Regarding myeloma, Burke also shares his experience with myeloma BsAbs, saying, “I follow the drug label, administer the drug ...

Yelena Y. Janjigian, MD, discusses the long-term survival data from the KEYNOTE-811 trial of pembrolizumab plus trastuzumab ...

The impact of physical and nutritional rehabilitation post bone marrow transplant in patients with hematologic malignancies ...